GlassScriptPhysician profile
Sunil J Vaidya
NPI 1144262346
$8,735.29
in general payments reported to CMS, 2019-2025
40 companies · $1,755 in 2025
The $1,755 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,059 · 2020: $818 · 2021: $1,052 · 2022: $908 · 2023: $1,423 · 2024: $1,720 · 2025: $1,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,453 · Education: $445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,453.08 |
| Education | $444.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,687.34 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Harmony Biosciences LLC | $1,449.76 | 2020-2025 | Wakix |
| Astrazeneca Pharmaceuticals LP | $1,153.51 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $666.80 | 2019-2025 | Ofev |
| Jazz Pharmaceuticals INC. | $643.54 | 2019-2025 | |
| Axsome Therapeutics, INC. | $512.34 | 2023-2025 | Sunosi |
| Mylan Specialty L.P. | $389.22 | 2019-2024 | Yupelri |
| Inspire Medical Systems, INC. | $377.29 | 2024-2025 | Inspire |
| Zoll Respicardia, INC. | $293.41 | 2019-2023 | Remede System |
| Merck Sharp & Dohme LLC | $198.87 | 2019-2025 | Keytruda, Keytruda Qlex |
| Genzyme Corporation | $156.85 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $107.85 | 2019 | |
| Shionogi INC | $100.97 | 2024 | Fetroja |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Novo Nordisk INC | $95.26 | 2025 | Wegovy |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Vaidya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.